cardiology

2026 ACC/AHA Dyslipidemia Guideline: A Comprehensive Pharmacotherapy Review

The 2026 ACC/AHA Dyslipidemia Guideline represents the most significant overhaul of lipid management since 2018 — introducing specific cholesterol targets and an expanded pharmacotherapeutic armamentarium.

Asundexian for Secondary Stroke Prevention OCEANIC-STROKE — A Three-Lens Critical Appraisal

OCEANIC-STROKE met its primary endpoint with a 26% relative reduction in ischemic stroke and no excess major bleeding — but the prespecified hierarchy broke at the 90-day endpoint. A statistician, a neurologist, and a researcher walk into a journal club. Here's what they each see.

Beyond Weight Loss: Reading the GLP-1 Side Effect Profile in Real Numbers A field guide for clinicians who are tired of being shown hazard ratios without denominators.

The Aspiration Anaerobe Myth What actually colonizes the aerodigestive tract — and why reflexive Zosyn for “possible aspiration” fails basic microbiology

Flecainide After PCI: 35 Years After CAST, Is It Time to Reconsider Class Ic Antiarrhythmics in Coronary Artery Disease?

PharmaCompass InPHARMation is for educational purposes only and does not constitute medical advice. Always verify clinical information before applying to patient care. Full Disclaimer | © 2026 PharmaCompass Education, LLC

Read more

Asundexian for Secondary Stroke Prevention OCEANIC-STROKE — A Three-Lens Critical Appraisal

Beyond Weight Loss: Reading the GLP-1 Side Effect Profile in Real Numbers A field guide for clinicians who are tired of being shown hazard ratios without denominators.

The Aspiration Anaerobe Myth What actually colonizes the aerodigestive tract — and why reflexive Zosyn for “possible aspiration” fails basic microbiology

Flecainide After PCI: 35 Years After CAST, Is It Time to Reconsider Class Ic Antiarrhythmics in Coronary Artery Disease?